13114-23-3

Basic information

• Product Name: 4-Methoxybenzaldehyde N-MethyliMine
• Synonyms: 4-Methoxybenzaldehyde N-MethyliMine;N-Methyl-4-methoxybenzimine
• CAS NO: 13114-23-3
• Molecular Formula: C₉H₁₁NO
• Molecular Weight: 165.18914
• Mol File: 13114-23-3.mol
• Article Data: 50

Chemical Properties

• Boiling Point: 233.1°Cat760mmHg
• Flash Point: 79.9°C
• Appearance: /
• Density: 0.94g/cm³
• Vapor Pressure: 0.0866mmHg at 25°C
• Refractive Index: 1.487
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-Methoxybenzaldehyde N-MethyliMine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methoxybenzaldehyde N-MethyliMine(13114-23-3)
• EPA Substance Registry System: 4-Methoxybenzaldehyde N-MethyliMine(13114-23-3)

Safety Data

• Hazardous Substances Data: 13114-23-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H11NO/c1-10-7-8-3-5-9(11-2)6-4-8/h3-7H,1-2H3/b10-7+

Upstream product

• 593-51-1 methylamine hydrochloride 
• 123-11-5 4-methoxy-benzaldehyde 
• 74-89-5 methylamine 
• 70972-89-3 N-Chlor-p-methoxy-benzylmethylamin 
• 98760-20-4 C₉H₁₂BrNO 
• 702-24-9 4-methoxy-N-methylbenzylamine 
• 96-31-1 N,N'-Dimethylurea 
• 75-52-5 nitromethane 

Downstream Products

• 54209-31-3 2,6-bis-(4-methoxy-phenyl)-3-methyl-2,3-dihydro-[1,3,5]oxadiazine-4-thione 
• 53059-79-3 2-{[1-(4-Methoxy-phenyl)-meth-(E)-ylidene]-amino}-N-methyl-2-phenyl-acetamide 
• 54209-17-5 6-(3,4-dichloro-phenyl)-2-(4-methoxy-phenyl)-3-methyl-2,3-dihydro-[1,3,5]oxadiazine-4-thione 
• 54209-28-8 2-(4-methoxy-phenyl)-3-methyl-6-p-tolyl-2,3-dihydro-[1,3,5]oxadiazine-4-thione 
• 54209-07-3 2-(4-methoxy-phenyl)-3-methyl-6-(4-nitro-phenyl)-2,3-dihydro-[1,3,5]oxadiazine-4-thione 
• 55881-68-0 3r-(4-methoxy-phenyl)-2-methyl-4c-phenyl-[1,2]thiazetidine 1,1-dioxide 
• 55881-68-0 3r-(4-methoxy-phenyl)-2-methyl-4t-phenyl-[1,2]thiazetidine 1,1-dioxide 
• 132525-52-1 N-<2-(1,4-dioxacyclohexyl)-p-methoxybenzyl>methylamine 
• 90490-27-0 (2S,3R)-2-(4-Methoxy-phenyl)-1-methyl-3-phenyl-aziridine 
• 86919-73-5 3-methyl-r-2-phenyl-t-4,c-5-di-(p-methoxyphenyl)oxazolidine 
• 86919-73-5 3-methyl-r-2-phenyl-c-4,t-5-di-(p-methoxyphenyl)oxazolidine 
• 116872-28-7 1-methylthio-3-(p-methoxyphenyl)-1,2-cyclopropanedicarboxylic acid diethyl ester 
• 124-40-3 dimethyl amine 
• 84065-86-1 3-tert-Butyl-2-(4-methoxyphenyl)-1-methyl-4-thioxo-3-azetidincarbonitril 

Relevant articles and documents

-

-

Enantioselective Reductive Coupling of Imines Templated by Chiral Diboron

We herein report a general, practical, and highly efficient method for asymmetric synthesis of a wide range of chiral vicinal diamines via reductive coupling of imines templated by chiral diboron. The protocol features high enantioselectivity and stereospecificity, mild reaction conditions, simple operating procedures, use of readily available starting materials, and a broad substrate scope. The method signifies the generality of diboron-enabled [3,3]-sigmatropic rearrangement.

Computationally Driven Structure Optimization, Synthesis, and Biological Evaluation of Imidazole-Based Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Inhibitors

Proprotein convertase subtilisin/kexin 9 (PCSK9) is responsible for the degradation of the hepatic low-density lipoprotein receptor (LDLR), which in turn regulates the circulating low-density lipoprotein cholesterol (LDL-C) level. For this reason, the PCSK9 inhibition, by small molecules or peptides, is a validated therapeutic approach for fighting hypercholesterolemia and cardiovascular diseases. In this field, we have recently reported an imidazole-based peptidomimetic that has shown PCSK9 inhibitory activity in the micromolar range. Here, by applying advanced computational techniques, the binding mechanism of that imidazole peptidomimetic was predicted. Then, among a small set of poly-imidazole analogs, compounds showing the highest theoretical affinity were suitably synthesized, relying on a van Leusen reaction based multicomponent strategy. One compound (named RIm13) displayed a PCSK9 inhibitory activity 10-fold lower than the template compound, and, remarkably, at a concentration of 1 μM, it successfully prevented the LDLR degradation mediated by PCSK9 on HepG2 cells. As well as increasing the LDL uptake at the same concentration, RIm13 represents currently one of the most potent small molecules targeting the PCSK9/LDLR protein-protein interaction.